Drug Delivery Partnering Agreements in Pharma and Biotech

Drug Delivery Partnering Agreements in Pharma and Biotech

Description

The Drug Delivery Partnering Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology or drug delivery-enabled product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 800 links to online copies of actual drug delivery contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of drug delivery dealmaking since 2000. The chapter includes numerous case studies to enable understanding of diagnostic dealmaking. Chapter 3 provides an overview of the trends in drug delivery dealmaking since 2000. Chapter 4 provides a review of the leading drug delivery deals since 2003. Deals are listed by headline value, signed by bigpharma, most active bigpharma, most active drug delivery companies, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of drug delivery contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of the leading 35 drug delivery companies with a brief summary followed by a comprehensive listing of drug delivery contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2003, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2000.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.

Key benefits

Drug Delivery Partnering Agreements in Pharma and Biotech provides the reader with the following key benefits:

In-depth understanding of drug delivery deal trends since 2000
Analysis of the structure of drug delivery agreements with numerous real life case studies
Comprehensive access to over 800 actual drug delivery contracts entered into by the world’s biopharma companies
Detailed access to actual drug delivery contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a drug delivery agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope

Drug Delivery Partnering Agreements in Pharma and Biotech is intended to provide the reader with an in-depth understanding of the drug delivery trends and structure of deals entered into by leading companies worldwide.

Drug Delivery Partnering Agreements in Pharma and Biotech includes:

Trends in drug delivery dealmaking in the biopharma industry since 2000
Analysis of drug delivery deal structure
Case studies of real-life drug delivery deals
Access to over 800 drug delivery contract documents
The leading drug delivery deals by value since 2000
Most active drug delivery dealmakers since 2000
The leading drug delivery partnering resources
In Drug Delivery Partnering Agreements in Pharma and Biotech, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Overview of drug delivery dealmaking

2.1. Introduction
2.2. The anatomy of drug delivery partnering
2.3. Drug delivery or specialty pharma?
2.3.1. Is specialty pharma the only way for drug delivery?
2.3.2. Best practice for optimizing drug delivery program development
2.2.3. The anatomy of a drug delivery deal
2.2.3.a. Case study 1: Alpharma – Durect – September 2008
2.2.3.b. Case study 2: Bayer – MDRNA – August 2007
2.2.3.c. Case study 3: Aradigm – Lung Rx – August 2007
Chapter 3 – Trends in drug delivery dealmaking

3.1. Introduction
3.2. Drug delivery partnering since 2000
3.3. Most active drug delivery dealmakers
3.4. Bigpharma drug delivery dealmaking activity
3.5. Bigpharma not active in drug delivery
3.6. Drug delivery partnering by deal type
3.6.1. Option and evaluation drug delivery partnering
3.7. Drug delivery partnering by disease type
3.8. Drug delivery M&A activity since 2000
Chapter 4 – Leading drug delivery deals

4.1. Introduction
4.2. Top drug delivery deals by value
4.3. Top drug delivery involving bigpharma
4.4. Leading drug delivery M&A deals by value
Chapter 5 – Bigpharma drug delivery deals

5.1. Introduction
5.2. How to use bigpharma drug delivery partnering deals
5.3. Bigpharma partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Lundbeck
Menarini
Merck & Co
Merck – Serono
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Procter & Gamble
Ratiopharm
Roche
Sanofi-Aventis
Schering Plough
Servier
Shire
Solvay
Takeda
Teva
UCB
Watson
Wyeth
Chapter 6 – Drug delivery company deals

5.1. Introduction
5.2. How to use drug delivery company partnering deals
5.3. Drug delivery partnering company profiles
3M Drug Delivery Systems
Alkermes
Altea Pharmaceuticals
Alza
Aradigm
Bioject
Biovail
Cardinal Health
Cima Labs
Connetics
Cydex Pharmaceuticals
Depomed
Dor Biopharma
Durect
Emisphere
Enzon
Ethypharm
Eurand
Generex
Inovio (formerly Genetronics)
Ivax
Macrochem
Macromed
MDRNA (formerly Nastech)
Nexmed
Noven
Penwest
Pherin Pharmaceuticals
Psivida
QLT
Skyepharma
Watson Pharmaceuticals
Zogenix
Chapter 7 – Drug delivery dealmaking directory

7.1. Introduction
7.2. Company A-Z
7.3. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
7.4. By deal type
Asset and product purchase
Collaborative R&D
Co-development
Co-marketing
Co-promotion
Development
Distribution
Joint venture
Licensing
M&A
Manufacturing
Marketing
Promotion
Option
Research
Supply
7.5. By therapy area
Cardiovascular
Central nervous system
Dermatology
Gastrointestinal
Genitourinary
Hematology
Immunology
Infection
Inflammation
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Animal health
Chapter 8 – Drug delivery partnering resource center

8.1. Online drug delivery partnering
8.2. Drug delivery partnering events
8.3. Further reading on drug delivery dealmaking
Appendices

Appendix 1 – Deal type definitions
Appendix 2 – Example drug delivery partnering agreement
About CurrentPartnering
Recent titles from CurrentPartnering
Figures in report

Figure 1: Components of the typical drug delivery deal structure
Figure 2: Best practice for drug delivery program development
Figure 3: Drug delivery partnering since 2000
Figure 4: Most active drug delivery dealmakers 2003-2008
Figure 5: Most active bigpharma signing drug delivery deals 2003-2008
Figure 6: Bigpharma – top 50 – drug delivery deals 2003 to 2008
Figure 7: Inactive bigpharma in drug delivery dealmaking 2003-2008
Figure 8: Drug delivery partnering by deal type since 2003
Figure 9: Drug delivery option deals since 2003
Figure 10: Drug delivery partnering by disease type from 2003
Figure 11: Drug delivery M&A since 2000
Figure 12: Top drug delivery deals by value since 2000
Figure 13: Top drug delivery deals signed by bigpharma value since 2000
Figure 14: Top drug delivery M&A deals by value since 2000
Figure 15: Online partnering resources
Figure 16: Forthcoming partnering events
Figure 17: Deal type definitions
Figure 18: Drug delivery partnering agreement between Solvay and Depomed, November 2008